SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Porwit Anna)
 

Search: WFRF:(Porwit Anna) > p53 is associated w...

  • Rodrigues, Joana M.Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments (author)

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-08-04
  • Wiley,2020
  • 10 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:9e86314d-2db7-4593-b245-bd380996cf1f
  • https://lup.lub.lu.se/record/9e86314d-2db7-4593-b245-bd380996cf1fURI
  • https://doi.org/10.1111/bjh.17023DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:144320398URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy-based treatments and have poor prognosis. Thus, there is a clinical need to identify missense mutations through routine analysis to enable patient stratification. Sequencing is not widely implemented in clinical practice for MCL, and immunohistochemistry (IHC) is a feasible alternative to identify high-risk patients. The aim of the present study was to investigate the accuracy of p53 as a tool to identify patients with TP53 missense mutations and the prognostic impact of overexpression and mutations in a Swedish population-based cohort. In total, 317 cases were investigated using IHC and 255 cases were sequenced, enabling analysis of p53 and TP53 status among 137 cases divided over the two-cohort investigated. The accuracy of predicting missense mutations from protein expression was 82%, with sensitivity at 82% and specificity at 100% in paired samples. We further show the impact of p53 expression and TP53 mutations on survival (hazard ratio of 3·1 in univariate analysis for both), and the association to risk factors, such as high MCL International Prognostic Index, blastoid morphology and proliferation, in a population-based setting.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hassan, MayLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH(Swepub:lu)ma5074ha (author)
  • Freiburghaus, CatjaLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH(Swepub:lu)food-cfi (author)
  • Eskelund, Christian W.Copenhagen University Hospital,University of Copenhagen (author)
  • Geisler, ChristianCopenhagen University Hospital (author)
  • Räty, RiikkaHelsinki University Central Hospital (author)
  • Kolstad, ArneOslo university hospital (author)
  • Sundström, ChristerUppsala University (author)
  • Glimelius, IngridKarolinska Institutet,Uppsala University (author)
  • Grønbæk, KirstenUniversity of Copenhagen,Copenhagen University Hospital (author)
  • Kwiecinska, AnnaKarolinska Institutet,Karolinska Institute(Swepub:lu)an6382kw (author)
  • Porwit, AnnaLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)an6742po (author)
  • Jerkeman, MatsLund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)onk-mje (author)
  • Ek, SaraLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)immt-san (author)
  • Gronbae, K (author)
  • Institutionen för immunteknologiInstitutioner vid LTH (creator_code:org_t)

Related titles

  • In:British Journal of Haematology: Wiley191:5, s. 796-8050007-10481365-2141

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view